NPPB and cancer: In a study on 555 patients with a primary diagnosis of cancer and no prior therapies, several biomarkers (including NT-proBNP, hs-TnT, mid-regional proatrial natriuretic peptide, proadrenomedullin, copeptin, and interleukin 6) were shown to increase with tumour progression.